NCT02100930View on ClinicalTrials.gov

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 7, 2019

Study Completion Date

March 7, 2019

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

Anti-GD2 3F8 Monoclonal Antibody

DRUG

GM-CSF (granulocyte-macrophage colony-stimulating factor)

DRUG

oral isotretinoin

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02100930 - Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | Biotech Hunter | Biotech Hunter